Last edition
News about "oral therapy candidate"
EIT Pharma Advances Lonafarnib Development with Extended Phase 3 Data
EIT Pharma presented extended analyses from its Phase 3 D-LIVR trial at The Liver Meeting, highlighting durable treatment responses following the cessation of lonafarnib-based therapy in chronic hepatitis D.
Oral Therapy Candidate | 13/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members